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Phosphoglycerate dehydrogenase (PHGDH) is an enzyme of serine biosynthesis overexpressed 
in various types of cancer. A new series of PHGDH inhibitors selectively block proliferation of 
PHGDH-dependent cancer cells and revealed an unexpected role of serine biosynthesis in 
coordinating one-carbon metabolism.  
Cancer cells are biosynthetic factories and gear multiple metabolic pathways towards cell growth and 
proliferation. Besides glucose and glutamine, serine is the third most consumed metabolite by cancer 
cells
1
, and it is used as building block for proteins and as carbon donor for nucleotide biosynthesis. 
Serine is a non-essential amino acids and can be synthesised de novo from glucose (Figure 1, left 
panel). Studies in the late 1980s demonstrated that de novo synthesis of serine is increased in cancer 
cells
2
, suggesting that this pathway might be relevant for cancer cell growth. It was not until the 
landmark discovery that phosphoglycerate dehydrogenase (PHGDH), the first step of de novo serine 
synthesis, is amplified in breast cancer
3
 and melanoma
4
, that this pathway came to the limelight. 
Importantly, silencing PHGDH in PHGDH-dependent cancers significantly affects their growth, 
making this enzyme an excellent target for cancer therapy. Recent work from Mullarky et al reported 
the discovery of a novel non-competitive inhibitor of PHGDH
6
. However, although this compound 
was selective against PHGDH-dependent melanoma and breast cancer cell lines, it was unstable in 
mouse plasma, limiting its use in vivo. In this issue of Nature Chemical Biology, Pacold et al. 
discovered small molecule inhibitors of PHGDH that exhibit potent antitumor activity both in vitro an 
in vivo
7
.  
PHGDH is now considered a bona fide oncogene and besides its amplification, its transcriptional 
activation by the antioxidant master regulator Nuclear factor (erythroid-derived 2)-like 2 (NRF2) was 
recently observed in lung cancer
5
. Inhibition of PHGDH decreases the growth and survival of 
PHGDH-dependent cancer cell lines even when extracellular serine is plentiful
 3-5 
This observation 
raised the possibility that PHGDH and glucose-derived serine metabolism have additional roles for 
cancer cells, besides providing building blocks for protein and nucleotide biosynthesis. In support of 
this hypothesis, it was shown that PHGDH harbours promiscuous enzymatic activity and catalyses the 
reduction of aKG to the oncometabolite 2-hydroxyglutarate
10
, which might explain the oncogenic 
function of PHGDH. Furthermore, it was observed that serine biosynthesis, via PSAT-dependent aKG 
production, contributes to up to 50% of the anaplerotic flux from glutamine
3
, emerging as a major 
determinant of mitochondrial function. Of note, both these functions are exquisite by-products of de 
novo serine synthesis and are independent of extracellular supply of serine. Yet, none of these studies 
investigated the fate of extracellular serine after silencing of PHGDH.  
To tackle this outstanding question, Pacold et al. set out to identify novel PHGDH inhibitors. Similar 
to Mullarky et al(REF) the authors developed an in vitro enzymatic assay to measure PHGDH activity 
by coupling the production of NADH generated by the conversion of 3-phosphoglycerate (3PG) to 
phosphohydroxy-pyruvate (pPyr) (Figure 1, light brown insert) to the diaphorase-mediated reduction 
of resazurin. They identified two potent piperazine-1-carbothioamide PHGDH inhibitors, NCT-502 
and NCT-503, and an “inactive compound” with a similar structure but with no activity against 
PHGDH. When tested on cell lines and xenograft tumours, PHGDH inhibitors exhibited a very potent 
anticancer activity against PHGDH-dependent cell lines but had not effects on PHGDH-independent 
counterparts, underlining their efficacy and on-target effect. Besides a very specific inhibition of 
serine biosynthesis, PHGDH inhibitors did not perturb the abundance of any other amino acids, with 
the exception of aspartate, found to be depleted upon PHGDH inhibition. This unexpected result 
revealed a mild mitochondrio-toxic activity of the two PHGDH inhibitors, shared also by the inactive 
compound.  
To examine the role of PHGDH for serine biosynthesis, Pacold et al. performed a comprehensive 
book-keeping of carbons from 
13
C-labelled serine and glucose using liquid chromatography mass-
spectrometry. They found that PHGDH inhibition not only affects serine biosynthesis from glucose 
but also reduces the incorporation of carbons from both extracellular and intracellular serine into 
nucleotides (Figure 1, right panel). Importantly, nucleotide depletion was mechanistically linked to 
cell cycle arrest observed upon PHGDH inhibition. In light of these results, Pacold et al. hypothesised 
that PHGDH inhibitors cause a mishandling of one-carbon units generated from serine. Indeed, 
additional functional experiments showed that when PHGDH is inhibited, the cytosolic enzyme 
Serine Hydroxymethyltransferase 1 (SHMT1), instead of extracting one-carbon units from serine to 
support nucleotide biosynthesis, regenerates serine from glycine instead, wasting one-carbon units 
(Figure 1, right panel). Consistently, deletion of SHMT1 using CRISPR-based genome editing was 
sufficient to redirect one-carbon units from serine to nucleotides biosynthesis and restored 
proliferation defects upon PHGDH inhibitors. 
Overall, the work presented by Pacold et al. uncovered a new facet of serine metabolism in PHGDH-
dependent cancer cells. However, few unanswered questions still remain. For instance, the authors did 
not investigate the mechanism of action of the novel PHGDH inhibitors. Their data indicate a non-
competitive mode of inhibition with respect to PHDH substrates, 3-PG and NAD
+
. This mechanism of 
action, similar to that of CBR-5884, the PHGDH inhibitor developed by Mullarky et al (REF), 
supports the presence of an allosteric pocket of PHGDH. It would be interesting to assess whether 
these compounds affect the oligomeric state of PHGDH, as shown for CBR-5884. From a biological 
point of view, the presented results demonstrate that in PHGDH-dependent cancer cells glucose-
derived serine biosynthesis coordinates one-carbon utilisation and, unexpectedly, SHMT1 
directionality. It is tempting to speculate that metabolites generated within serine biosynthesis exert a 
regulatory function on SHMT1. However, the details of this feedback mechanism are still unknown. 
Finally, these results suggest that cancer cells can discriminate intra- and extracellular serine. It is 
possible that this type of selective usage of substrates is achieved by a tight compartmentalization of 
the underpinning metabolic pathways. Hopefully, the compounds developed by Pacold et al. will shed 
some light on this fascinating conundrum of cell metabolism.  
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Figure Legend.  
Figure 1. Schematic representation of serine metabolism and effects of PHGDH inhibitor NCT-
503. In untreated PHGDH-dependent cells, glucose is diverted towards serine biosynthesis to provide 
one-carbon units for nucleotide synthesis and aKG for anaplerosis. PHGDH inhibitor NCT-503 
selectively blocks glucose-derived serine synthesis but at the same time triggers SHMT1-dependent 
one-carbon units wasting to synthesize serine from glycine. This futile cycle depletes the cell of 
nucleotides and leads to cell cycle arrest. The light brown insert in the left panel indicates the three 
enzymes used for the in vitro PHGDH-inhibitors screening. Pyr=pyruvate; 3PG=3-phosphoglycerate; 
pPyr=phosphohydroxy-pyruvate; pSer=phosphoserine; PSAT= phosphoserine aminotransferase; 
PSPH= phosphoserine phosphatase; akG=alpha-ketoglutarate; THF=tetrahydrofolate; meTHF= 5,10-
methylene THF; fTHF=formyl THF; SHMT1/2= serine hydroxymetyl transferase 1/2; TCA 
cycle=tricarboxylic acid cycle  
 
